DekaBank Deutsche Girozentrale Reduces Stake in DexCom, Inc. (NASDAQ:DXCM)

DekaBank Deutsche Girozentrale lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 20.7% during the first quarter, HoldingsChannel reports. The fund owned 837,620 shares of the medical device company’s stock after selling 218,494 shares during the period. DekaBank Deutsche Girozentrale’s holdings in DexCom were worth $116,284,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in DXCM. Vanguard Group Inc. boosted its position in shares of DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after purchasing an additional 136,282 shares during the period. Capital Research Global Investors boosted its position in shares of DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares during the period. Sands Capital Management LLC boosted its position in shares of DexCom by 10.2% in the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after purchasing an additional 1,398,136 shares during the period. Capital World Investors boosted its position in shares of DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares during the period. Finally, Artisan Partners Limited Partnership boosted its position in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM traded up $1.98 during trading on Friday, hitting $72.30. 7,633,973 shares of the stock were exchanged, compared to its average volume of 7,607,828. The company has a market cap of $28.97 billion, a PE ratio of 46.65, a P/E/G ratio of 2.18 and a beta of 1.16. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company has a fifty day moving average price of $109.33 and a two-hundred day moving average price of $121.82. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. DexCom’s revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.34 earnings per share. On average, analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on DXCM shares. Piper Sandler decreased their target price on DexCom from $150.00 to $90.00 and set an “overweight” rating for the company in a research report on Friday, July 26th. Redburn Atlantic assumed coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 target price on the stock. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. BTIG Research decreased their price target on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. Finally, Royal Bank of Canada dropped their price objective on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $111.50.

Insider Buying and Selling

In related news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the transaction, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the transaction, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the transaction, the executive vice president now owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The disclosure for this sale can be found here. Insiders have sold 4,135 shares of company stock worth $446,797 in the last three months. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.